Migraine and the Immune System: Inflammation, Autoimmunity, and Susceptibility

The relationship between migraine and the immune system is more complex and more clinically significant than is commonly recognized. Migraine has historically been understood primarily as a neurological condition, and while that framing is correct, it is incomplete. The immune system and its inflammatory mediators play active roles in migraine pathophysiology, both during attacks and in the interictal period between them. Understanding these immune-neurological interactions provides insight into why certain conditions that involve immune dysregulation are associated with altered migraine patterns, and why some anti-inflammatory approaches may have a role in migraine management.

Neuroinflammation and the Migraine Attack

Neuroinflammation, the activation of inflammatory processes within and surrounding the nervous system, is a central feature of migraine attacks rather than an incidental finding. When the trigeminovascular system is activated during a migraine attack, trigeminal nerve fibers release inflammatory neuropeptides including calcitonin gene-related peptide, substance P, and neurokinin A. These neuropeptides initiate a cascade of inflammatory changes in the meningeal tissues that both produces and perpetuates migraine pain.

Mast cells, which are innate immune cells resident in the dura mater, are activated by substance P and degranulate to release histamine, serotonin, and prostaglandins. These immune mediators further sensitize trigeminal nerve endings and amplify the inflammatory response. The interaction between the nervous system and these resident immune cells in the meninges represents a neuroimmune interface that is directly relevant to the generation and maintenance of migraine pain.

Systemic markers of inflammation, including elevated levels of interleukin-1 beta, interleukin-6, and tumor necrosis factor-alpha, have been documented during migraine attacks in multiple studies. These pro-inflammatory cytokines can cross the blood-brain barrier and influence central pain processing, potentially contributing to central sensitization and the broader symptom burden of the migraine attack.

The Interictal Inflammatory State

Neuroinflammation in migraine is not limited to the period of active attacks. Research has documented elevated inflammatory markers in people with migraine even during the interictal period, the time between attacks when symptoms have resolved. This chronic low-grade neuroinflammation may contribute to the sustained lowering of the migraine threshold that characterizes the condition and may play a role in the transition from episodic to chronic migraine.

C-reactive protein, a nonspecific marker of systemic inflammation, is modestly elevated in people with frequent migraine compared to those without the condition. Interleukin-6, which promotes the production of C-reactive protein and has direct effects on neuronal excitability, is elevated interictally in chronic migraine patients. These findings suggest that migraine involves a degree of ongoing immune activation that persists beyond individual attacks.

Migraine and Autoimmune Conditions

Several autoimmune conditions are associated with altered migraine patterns. Lupus erythematosus, an autoimmune condition characterized by widespread inflammation, is associated with elevated migraine prevalence. The inflammatory mediators and antiphospholipid antibodies associated with lupus may directly influence the vascular and neurological systems involved in migraine.

Celiac disease, an autoimmune condition triggered by gluten, is associated with higher rates of migraine compared to the general population. Neurological manifestations of celiac disease, including migraine, may reflect the systemic inflammatory state and possible neurological antibody production associated with active disease.

Antiphospholipid syndrome, characterized by antibodies that increase clotting risk, is associated with elevated migraine rates and with migraine with aura specifically. The prothrombotic state and endothelial effects of antiphospholipid antibodies may influence cerebrovascular function in ways that increase migraine susceptibility.

Anti-Inflammatory Approaches to Migraine Management

The role of neuroinflammation in migraine pathophysiology provides a rationale for anti-inflammatory management approaches, though the evidence base for specific interventions varies considerably.

Nonsteroidal anti-inflammatory drugs are effective acute migraine treatments in part because they inhibit prostaglandin synthesis, directly reducing the inflammatory contribution to meningeal sensitization. Dietary approaches that reduce systemic inflammation, including increased omega-3 fatty acid intake and adherence to a Mediterranean-style dietary pattern, have been associated with reduced migraine frequency in some observational studies.

Magnesium, which has anti-inflammatory properties in addition to its effects on neuronal excitability and vascular function, has shown benefit as a migraine preventive in some randomized controlled trials, possibly through multiple overlapping mechanisms including its influence on inflammatory signaling.